|Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors|
T. Roux1, M. Badol1, N. Douayry1, L. Sergeant1, E.Trinquet1, F. Degorce1, S. Milhas2, S. Betzi2, C. Derviaux2, C. Eydoux3, J. Letienne2, A. Lugari2, Y. Collette2, J-C. Guillemot3 et X. Morelli2
Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.
|Automated Fluorescence Detection and Imaging of RNA Species in Live Cells|
Paul Held, Victor Koong, Don Weldon, Peter Banks
This poster describes the detection and quantification of RNA species in Live cells through automated imaging.
|Artificial Multi-Gene Expression Systems Design Service for Natural Compound Formation and Hetero Protein Complexes|
Bernauer, Hubert, Gregor Zipf and Josef Maier
Drug discovery of natural compounds drug development and drug target analyses as well as bioproduction can benefit from artificial genetic systems and constructions. The direction in which genes are to be developed is written in the genomes. Synthesis oriented genomic analyses of codon bias and tRNA adaption analyses are prerequisites for generating adaptive, highly functional genes.
|Validation of a Novel Tumoroid-Based Cell Culture Model to Perform 3D in vitro Cell Signaling Analyses|
Brad Larson 1, Grant Cameron 2, Nicolas Pierre 3, and Peter Banks 1
Here we demonstrate an in vitro HTRF® microplate assay that can quantify total, as well as phosphorylated elF4E.
|Validation of a 3-Dimensional Human Liver Microtissue Model for Long-term Hepatotoxicity Studies|
Brad Larson1, Stewart Hunt2, Timothy Moeller3, Diana Long4, and Peter Banks1
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drug commonly used as analgesics and antipyretics, as well as for management of rheumatological disorders. They are one of the most highly prescribed drug families around the world, and consequently, along with antimicrobial agents, are the most frequent causes of druginduced liver injury (DILI) (Bjornsson et al., 2010).
|Characterization of Proteins and Protein Self Association (Oligomerization) with SEC-MALS|
Michel Terray, Mark Pothecary
In this poster, a series of proteins and their oligomers were characterized using SEC-MALS with UV and RI detection. The monomer molecular weights are measured and compared with those from column calibration. The molecular weights of their oligomers are also compared with column calibration and the differences explored.
|Identifying Molecular Signatures of Tumors Using Novel Fluorescence Resonance Energy Transfer Networks|
Vishwa Nellore, Chris Dwyer
We developed FRET sensors that can detect 125 fluorophores simultaneously. From experimental analyses of over 1200 time-resolved fluorescence signatures on 300 prototypical sensors, we show that the optical responses are highly repeatable and minor variations between FRET networks can be discriminated resulting in a total of 10^375 unique responses in theory.
|Amino-Coated Metallofullerene Nanoparticles for Glioblastoma Mutiforme Tumor Detection|
Tinghui Li , Susan. Murphy, Kanwarpal Bakshi, Steven LaConte, Zhi Sheng, and Harry Dorn
We report the preparation of a new functionalized trimetallic nitride endohedral metallofullerene, with a cage surface consisting of positively charged amino groups, which is expected to bind more efficiently to negatively charged cell phospholipid bi-layer cellular surfaces and will more readily undergo endocytosis. We now report that this Gd-nanoplatform when subsequently conjugated with an IL-13 peptide, (IL-13-Gd3N@C80(OH)x(NH2)y) exhibits enhanced targeting of U-251 GBM cell lines.
|Liposomes and Nanoparticles as Delivery Vehicles for the Treatment of Lung Diseases|
Raisa Kiseleva1, Jennifer Mulligan2, Carl Atkinson2, Rodney Schlossser2, Alexey Vertegel1
Targeted nanoparticle-based drug delivery to the lungs is an emerging area of interest for both scientists and medical workers because it allows better drug retention in the lungs and can provide prolonged drug release. In our study we investigated the potential of using liposomes and polymeric nanoparticles surface modified with a specific antibody as drug carriers for targeted drug delivery to the lungs.